GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
To date, there have been no Canadian led neoadjuvant or peri-operative trials, this
multicentre design gives the opportunity to build more experience with this strategy across
Canada in more institutions. The design of this prospective trial will also test our
important hypotheses regarding the use of biomarkers to understand the benefit of mFFX in
improving outcomes for patients with resectable pancreas cancer. Data from this study would
likely inform future studies where patients are given personalised options for the best
treatment strategies rather than one empiric approach.
Phase:
N/A
Details
Lead Sponsor:
University Health Network, Toronto
Collaborators:
Cancer Care Ontario Pancreatic Cancer Canada Pancreatic Cancer Canada Foundation